A study using the flavonol fisetin combined with rt-PA in stroke patients shows that the addition of this flavonoid extends the therapeutic window of rt-PA treatment and dramatically improves the neurological deficits evaluated by the National Institutes of Health Stroke Scale (NIHSS) and decreases the plasma levels of C-reactive protein (CRP) and matrix metalloproteinases (MMP)-2 and -9 [134]. The gene discussed is CRP; the disease is stroke disorder.